- Waldenström Macroglobulinemia
- Melanoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Childhood Cancers
- Gastric Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Immunotherapy
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma Cancer
- Mesothelioma
- MPN
- MDS
- Myeloma
- Prostate Cancer
- Rare Cancers
- Sarcoma
- Skin Cancer
- Testicular Cancer
- Thyroid Cancer
From Cancer to Capitol Hill
In this week’s episode of CURE Talks Cancer, we speak with Rose Gerber, director of patient advocacy at CPAN, about her experience with breast cancer, how she became an advocate and how her journey helped her to see beyond the cancer experience.
As a young mother, Rose Gerber faced a HER2-positive breast cancer diagnosis at an early stage in life — and during a time where this disease had poorer outcomes. Despite this feat, Rose used her personal experience, in combination with her professional skillset, to help other patients with cancer through the Community Oncology Alliance Patient Advocacy Network (CPAN).
Since, Rose — who is the director of patient advocacy at CPAN – has met with legislators on Capitol Hill to discuss cancer policy issues and has also assisted in developing programs across the country.
In this week’s episode of CURE Talks Cancer, we speak with Rose about her experience with breast cancer, how she became an advocate and how her journey helped her to see beyond the cancer experience.
To learn more, visit the CPAN site on curetoday.com.
In this week’s episode of CURE Talks Cancer, we speak with Rose Gerber, director of patient advocacy at CPAN, about her experience with breast cancer, how she became an advocate and how her journey helped her to see beyond the cancer experience.
Tecentriq Plus Perjeta, Chemo Does Not Improve pCR in HER2+ Breast Cancer
December 8th 2023A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete response in patients with HER2-positive operable breast cancer.
Read More
Fertility Research ‘Long Overdue’ for Patients With Cervical Cancer
November 30th 2023Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’
Listen
